Valneva’s (VALN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock.

Separately, Guggenheim lowered their price target on Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, March 24th.

Valneva Stock Down 3.8 %

Shares of VALN traded down $0.26 during mid-day trading on Wednesday, hitting $6.52. 3,778 shares of the company’s stock were exchanged, compared to its average volume of 36,375. The stock has a market cap of $529.42 million, a price-to-earnings ratio of -50.12 and a beta of 1.85. The firm has a fifty day moving average of $6.95 and a two-hundred day moving average of $5.62. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50.

Valneva (NASDAQ:VALN) last posted its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. On average, sell-side analysts forecast that Valneva will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

Institutional investors have recently added to or reduced their stakes in the stock. ABC Arbitrage SA bought a new position in shares of Valneva during the 4th quarter worth approximately $84,000. GAMMA Investing LLC bought a new position in shares of Valneva during the first quarter valued at $94,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.